Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1996 1
1997 7
1998 1
1999 6
2000 5
2001 3
2002 4
2003 7
2004 5
2005 6
2006 7
2007 12
2008 10
2009 14
2010 11
2011 6
2012 9
2013 7
2014 11
2015 7
2016 5
2017 6
2018 8
2019 13
2020 19
2021 19
2022 15
2023 14
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

221 results

Results by year

Filters applied: . Clear all
Page 1
LILRB4, an immune checkpoint on myeloid cells.
Yang T, Qian Y, Liang X, Wu J, Zou M, Deng M. Yang T, et al. Blood Sci. 2022 May 17;4(2):49-56. doi: 10.1097/BS9.0000000000000109. eCollection 2022 Apr. Blood Sci. 2022. PMID: 35957669 Free PMC article. Review.
Leukocyte immunoglobulin-like receptor B4 (LILRB4) is an inhibitory receptor in the LILR family mainly expressed on normal and malignant human cells of myeloid origin. ...In normal myeloid cells, LILRB4 regulates intrinsic cell activation and differentiation. In dis …
Leukocyte immunoglobulin-like receptor B4 (LILRB4) is an inhibitory receptor in the LILR family mainly expressed on normal and malign …
LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration.
Deng M, Gui X, Kim J, Xie L, Chen W, Li Z, He L, Chen Y, Chen H, Luo W, Lu Z, Xie J, Churchill H, Xu Y, Zhou Z, Wu G, Yu C, John S, Hirayasu K, Nguyen N, Liu X, Huang F, Li L, Deng H, Tang H, Sadek AH, Zhang L, Huang T, Zou Y, Chen B, Zhu H, Arase H, Xia N, Jiang Y, Collins R, You MJ, Homsi J, Unni N, Lewis C, Chen GQ, Fu YX, Liao XC, An Z, Zheng J, Zhang N, Zhang CC. Deng M, et al. Nature. 2018 Oct;562(7728):605-609. doi: 10.1038/s41586-018-0615-z. Epub 2018 Oct 17. Nature. 2018. PMID: 30333625 Free PMC article.
Deletion of LILRB4 or the use of antibodies to block LILRB4 signalling impeded AML development. ...LILRB4 represents a compelling target for the treatment of monocytic AML....
Deletion of LILRB4 or the use of antibodies to block LILRB4 signalling impeded AML development. ...LILRB4 represents a …
LILRB4, from the immune system to the disease target.
Liu J, Wu Q, Shi J, Guo W, Jiang X, Zhou B, Ren C. Liu J, et al. Am J Transl Res. 2020 Jul 15;12(7):3149-3166. eCollection 2020. Am J Transl Res. 2020. PMID: 32774691 Free PMC article. Review.
Differential expression of LILRB4 is present in a variety of immune system diseases, such as Kawasaki disease, systemic lupus erythematosus (SLE), and sepsis. Recent studies have shown that LILRB4 also plays a role in mental illness. The important role of LILRB4 …
Differential expression of LILRB4 is present in a variety of immune system diseases, such as Kawasaki disease, systemic lupus erythem …
LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy.
Sharma N, Atolagbe OT, Ge Z, Allison JP. Sharma N, et al. J Exp Med. 2021 Jul 5;218(7):e20201811. doi: 10.1084/jem.20201811. Epub 2021 May 11. J Exp Med. 2021. PMID: 33974041 Free PMC article.
LILRB4, known as gp49B in mice, is a LILRB family receptor. Human and murine LILRB4 have two extracellular domains but differ in the number of intracellular ITIMs (three versus two). We observed a high correlation in LILRB4 expression with other immune inhibi …
LILRB4, known as gp49B in mice, is a LILRB family receptor. Human and murine LILRB4 have two extracellular domains but differ …
LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells.
Li Z, Deng M, Huang F, Jin C, Sun S, Chen H, Liu X, He L, Sadek AH, Zhang CC. Li Z, et al. Cell Mol Immunol. 2020 Mar;17(3):272-282. doi: 10.1038/s41423-019-0321-2. Epub 2019 Nov 7. Cell Mol Immunol. 2020. PMID: 31700117 Free PMC article.
We constructed chimeric proteins containing the extracellular domain of LILRB4 and the intracellular domain of LILRB1 and vice versa. The intracellular domain of LILRB4, but not that of LILRB1, mediates T-cell suppression and AML cell migration. Our studies thus def …
We constructed chimeric proteins containing the extracellular domain of LILRB4 and the intracellular domain of LILRB1 and vice versa. …
LILRB4 Checkpoint for Immunotherapy: Structure, Mechanism and Disease Targets.
Xiang Z, Yin X, Wei L, Peng M, Zhu Q, Lu X, Guo J, Zhang J, Li X, Zou Y. Xiang Z, et al. Biomolecules. 2024 Feb 4;14(2):187. doi: 10.3390/biom14020187. Biomolecules. 2024. PMID: 38397424 Free PMC article. Review.
Thus, LILRB4 has emerged as a key player in addressing autoimmune diseases, transplant tolerance induction, and other medical issues. ...By exploring the involvement of LILRB4 in various diseases, its significance in disease progression is emphasized. ...
Thus, LILRB4 has emerged as a key player in addressing autoimmune diseases, transplant tolerance induction, and other medical issues. …
Molecular regulatory mechanism of LILRB4 in the immune response.
Liu H, Yang J, Zhang J, Zhang P, Zhang M, Yang C, Liu L, Huang C, Wang W, Zhai Y, Yang J. Liu H, et al. Cent Eur J Immunol. 2023;48(1):43-47. doi: 10.5114/ceji.2023.125238. Epub 2023 Feb 23. Cent Eur J Immunol. 2023. PMID: 37206591 Free PMC article. Review.
This imbalance is regulated by many factors, both negative and positive. Leukocyte immunoglobulin-like receptor B4 (LILRB4) is a member of leukocyte immunoglobulin-like receptors (LILRs). ...In addition, many factors can induce the expression of LILRB4, such as vita …
This imbalance is regulated by many factors, both negative and positive. Leukocyte immunoglobulin-like receptor B4 (LILRB4) is a memb …
LILRB4-targeting Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia.
Anami Y, Deng M, Gui X, Yamaguchi A, Yamazaki CM, Zhang N, Zhang CC, An Z, Tsuchikama K. Anami Y, et al. Mol Cancer Ther. 2020 Nov;19(11):2330-2339. doi: 10.1158/1535-7163.MCT-20-0407. Epub 2020 Sep 2. Mol Cancer Ther. 2020. PMID: 32879051 Free PMC article.
Here, we test whether LILRB4 is a promising ADC target to kill monocytic AML cells while sparing healthy counterparts. ...Our ADC linker technology platform efficiently generated homogeneous anti-LILRB4 ADCs with defined drug-to-antibody ratios. The homogeneous anti …
Here, we test whether LILRB4 is a promising ADC target to kill monocytic AML cells while sparing healthy counterparts. ...Our ADC lin …
LILRB4 regulates the function of decidual MDSCs via the SHP-2/STAT6 pathway during Toxoplasma gondii infection.
Li Y, Guo J, Zhang H, Li Z, Ren Y, Jiang Y, Liu X, Hu X. Li Y, et al. Parasit Vectors. 2023 Jul 17;16(1):237. doi: 10.1186/s13071-023-05856-4. Parasit Vectors. 2023. PMID: 37461040 Free PMC article.
METHODS: LILRB4-deficient (LILRB4(-/-)) pregnant mice infected with T. gondii with associated adverse pregnancy outcomes, and anti-LILRB4 neutralized antibodies-treated infected human dMDSCs were used in vivo and in vitro experiments, respectively. The aim wa …
METHODS: LILRB4-deficient (LILRB4(-/-)) pregnant mice infected with T. gondii with associated adverse pregnancy outcomes, and …
Prognostic impact of LILRB4 expression on tumor-infiltrating cells in resected non-small cell lung cancer.
Kumata S, Notsuda H, Su MT, Saito-Koyama R, Tanaka R, Suzuki Y, Funahashi J, Endo S, Yokota I, Takai T, Okada Y. Kumata S, et al. Thorac Cancer. 2023 Jul;14(21):2057-2068. doi: 10.1111/1759-7714.14991. Epub 2023 Jun 8. Thorac Cancer. 2023. PMID: 37290427 Free PMC article.
RESULTS: The LILRB4 (high) group, in which patients with a high LILRB4 expression level on tumor-infiltrating cells, showed a shorter overall survival (OS) (p = 0.013) and relapse-free survival (RFS) (p = 0.0017) compared to the LILRB4 (low) group. ...Even in …
RESULTS: The LILRB4 (high) group, in which patients with a high LILRB4 expression level on tumor-infiltrating cells, showed a …
221 results